1,275 results on '"Hung, Chien-Ching"'
Search Results
2. Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV
3. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study
4. Hypogonadism among HIV-positive men who have sex with men in Taiwan: Prevalence and associated factors
5. Complete response to front-line therapies is associated with long-term survival in HIV-related lymphomas in Taiwan
6. Clinical manifestations and risk factors for COVID-19 and its severity in patients with hematological malignancies
7. Effect of early dexamethasone on outcomes of COVID-19: A quasi-experimental study using propensity score matching
8. Comparable clinical outcomes with same-day versus rapid initiation of antiretroviral therapy in Taiwan
9. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
10. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials
11. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 and hepatitis B coinfection (ALLIANCE): a double-blind, multicentre, randomised controlled, phase 3 non-inferiority trial
12. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound
13. Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
14. Evolution of neutralizing antibodies and cross-activity against different variants of SARS-CoV-2 in patients recovering from COVID-19
15. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial
16. Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study
17. Patient-reported outcomes among virally suppressed people living with HIV after switching to Co-formulated bictegravir, emtricitabine and tenofovir alafenamide
18. Risky sexual practices and hepatitis C viremia among HIV-positive men who have sex with men in Taiwan
19. Recommendations and guidelines for the diagnosis and management of Coronavirus Disease-19 (COVID-19) associated bacterial and fungal infections in Taiwan
20. Epidemiology, clinical features, and outcomes of strongyloidiasis in Taiwan from 1988 to 2020: A case series and literature review
21. Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation
22. Coexistent diffuse large B-cell lymphoma and disseminated Mycobacterium avium complex infection in a person with AIDS
23. Impact of the initial wave of COVID-19 pandemic in Taiwan on local HIV services: Results from a cross-sectional online survey
24. Impact of coronavirus disease 2019 on the HIV testing and health care delivery at a university hospital in Taiwan, 2020–2021
25. Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression
26. Incidence of low-level viremia and its impact on virologic failure among people living with HIV-1 who switched to elvitegravir-based antiretroviral therapy
27. Disseminated Mycobacterium chimaera infection in a patient with adult-onset immunodeficiency syndrome: case report
28. Care cascade of tuberculosis infection treatment for people living with HIV in the era of antiretroviral therapy scale-up
29. Non-opioid recreational drug use and a prolonged HIV outbreak among men who have sex with men in Taiwan: An incident case-control study, 2006–2015
30. Sexually transmitted coinfections among at-risk HIV-positive MSM: implications for optimal preemptive treatment
31. Under-utilization of statins among people with HIV who were aged 40 years or older
32. High prevalence of sexually transmitted coinfections among at-risk people living with HIV
33. Seroepidemiology of the human herpesvirus 8 infection among people living with HIV in Taiwan, 2014–2018
34. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression
35. Comparisons of Serologic Responses of Early Syphilis to Treatment with a Single-Dose Benzathine Penicillin G Between HIV-Positive and HIV-Negative Patients
36. Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
37. Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis
38. Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan
39. Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy
40. Dual therapy with dolutegravir plus boosted protease inhibitor as a maintenance or salvage therapy in highly experienced people living with HIV
41. Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
42. Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan
43. Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People With HIV.
44. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
45. Trends of recent hepatitis C virus infection among HIV-positive men who have sex with men in Taiwan, 2011–2018
46. Weight gain and dyslipidemia among virally suppressed HIV-positive patients switching to co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
47. Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study
48. Polypharmacy and potential drug-drug interactions among people living with HIV in the era of integrase strand-transferase inhibitor-based antiretroviral therapy
49. Weight and metabolic changes among virally suppressed people with HIV who switched to co-formulated bictegravir/emtricitabine/tenofovir alafenamide
50. Epidemiology and risk factors of Japanese encephalitis in Taiwan, 2010–2022
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.